238 related articles for article (PubMed ID: 32603666)
1. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Thompson BR; Shi J; Zhu HJ; Smith DE
Biochem Pharmacol; 2020 Oct; 180():114127. PubMed ID: 32603666
[TBL] [Abstract][Full Text] [Related]
2. A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
Wang Y; Wang G; Chen H; Sun Y; Sun M; Liu X; Jian W; He Z; Sun J
Int J Pharm; 2020 Jan; 573():118718. PubMed ID: 31756441
[TBL] [Abstract][Full Text] [Related]
3. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.
Tao XM; Wang JC; Wang JB; Feng Q; Gao SY; Zhang LR; Zhang Q
Eur J Pharm Biopharm; 2012 Oct; 82(2):401-9. PubMed ID: 22728546
[TBL] [Abstract][Full Text] [Related]
5. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
[TBL] [Abstract][Full Text] [Related]
6. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
7. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
Joshi G; Kumar A; Sawant K
Eur J Pharm Sci; 2014 Aug; 60():80-9. PubMed ID: 24810394
[TBL] [Abstract][Full Text] [Related]
9. Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs.
Wang G; Chen H; Zhao D; Ding D; Sun M; Kou L; Luo C; Zhang D; Yi X; Dong J; Wang J; Liu X; He Z; Sun J
J Med Chem; 2017 Mar; 60(6):2552-2561. PubMed ID: 28234466
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats.
Zhao C; Li Y; Qin Y; Wang R; Li G; Sun C; Qu X; Li W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1541-50. PubMed ID: 23564376
[TBL] [Abstract][Full Text] [Related]
13. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
14. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
16. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
17. Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.
Chu W; Tian P; Ding N; Cai Q; Li J; Zhuo X; Tang Z; Gou J; Yin T; Zhang Y; He H; Tang X
Pharm Res; 2018 Oct; 35(12):230. PubMed ID: 30327887
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa P; Immordino ML; Rocco F; Cattel L
Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
[TBL] [Abstract][Full Text] [Related]
20. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
